Equity intelligence report • May 31, 2026
Viking Therapeutics has solidified its status in the biopharmaceutical sector following successful completion of its Phase 3 VANQUISH-1 trial for VK2735, its obesity treatment. However, the company is facing financial scrutiny, reporting significant net losses and lower price targets from analysts due to concerns over its valuation, especially as its cash reserve stands at $706 million against a market cap of approximately $3.74 billion. Despite institutional investors showing mixed sentiments, with some increasing their stakes, the company’s stock remains volatile amid broader market concerns. Upcoming clinical data and the potential for VK2735 may provide crucial catalysts for recovery.
Click a month on the chart to update the report below.